Insilico Medicine

From H+Pedia
Jump to: navigation, search
Insilico Medicine is an artificial intelligence company focusing on drug discovery, biomarker…[1]

Insilico Medicine is an American biotechnology company based based out of Johns Hopkins University’s Emerging Technology Center and headquartered in Rockville, Maryland. The company combines genomics, big data analysis, and deep learning for in silico drug discovery. The company was founded in 2014 by transhumanist Alex Zhavoronkov to provide alternatives to animal testing for research and development programs in the pharmaceutical industry. By using artificial intelligence and deep-learning techniques, Insilico is able to analyze how a compound will affect cells and what drugs can be used to treat the cells in addition to possible side effects. Through its Pharma.AI division, the company provides machine learning services to different pharmaceutical, biotechnology, and skin care companies. A core focus area is anti-aging drugs and the discovery of aging related biomarkers.[2] For instance, they have created the young.ai and aging.ai platforms and entered into a partnership with Life Extension, a nutropheuticals company.[3] Insilico is known for hiring mainly through hackathon competitions which they run globally.

The company has multiple collaborations in the applications of next-generation artificial intelligence technologies such as the generative adversarial networks and reinforcement learning to the generation of novel molecular structures with desired properties.

In 2017, Insilico was named one of the Top 5 AI companies by NVIDIA for its potential for social impact.[4]

External links

References

  1. https://medium.com/insilicomedicine/the-new-era-for-ai-powered-drug-discovery-and-longevity-biotechnology-begins-for-insilico-following-c93e6efab423
  2. Can artificial intelligence aid human age-reversal? Digital Journal
  3. Life Extension partnership with InSilico
  4. Zhavoronkov, Alex (11 June 2018). [ "The new era for AI-powered drug discovery and longevity biotechnology begins for Insilico following…"]. Medium. "{{{quote}}}"